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OBJECTIVE—Various cutoff levels of hemoglobin A1c (A1C) have been suggested to screen
for diabetes, although more consensus about the best level, especially for different ethnicities, is
required. We evaluated the usefulness of A1C levels when screening for undiagnosed diabetes
and as a predictor of 6-year incident diabetes in a prospective, population-based cohort study.
RESEARCH DESIGN AND METHODS—A total 10,038 participants were recruited
from the Ansung-Ansan cohort study. All subjects underwent a 75-g oral glucose tolerance test
at baseline and at each biennial follow-up. Excluding subjects with a previous history of diabetes
(n=572),thereceiveroperatingcharacteristiccurvewasusedtoevaluatethediagnosticaccuracy
of the A1C cutoff. The Cox proportional hazards model was used to predict diabetes at 6 years.
RESULTS—At baseline, 635 participants (6.8%) had previously undiagnosed diabetes. An
A1C cutoff of 5.9% produced the highest sum of sensitivity (68%) and speciﬁcity (91%). At 6
years, 895 (10.2%) subjects had developed incident diabetes. An A1C cutoff of 5.6% had the
highestsum of sensitivity(59%) and speciﬁcity(77%)for theidentiﬁcationofsubsequent6-year
incident diabetes. After multivariate adjustment, men with baseline A1C $5.6% had a 2.4-fold
increased risk and women had a 3.1-fold increased risk of new-onset diabetes.
CONCLUSIONS—A1Cisaneffectiveandconvenientmethodfordiabetesscreening.AnA1C
cutoff of 5.9% may identify subjects with undiagnosed diabetes. Individuals with A1C $5.6%
have an increased risk for future diabetes.
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T
he prevalence of type 2 diabetes is
increasing rapidly. In the U.S.,
.13% of adults have been diag-
nosed with type 2 diabetes (1), and a sim-
ilar prevalence has been reported in Asia
(2). Up to 25% of newly diagnosed dia-
betic patients already had microvascular
complications, which suggests that there
isa6-to7-yeartimelagbetweentheonset
and the diagnosis of type 2 diabetes (3).
When considering the clinical impli-
cations of diabetes and its complications,
itisimportanttoidentifyindividualswith
undiagnosed diabetes or those who are
prone to diabetes in the near future. The
American Diabetes Association (ADA)
recommends screening asymptomatic
people at 3-year intervals using a fasting
plasma glucose (FPG) test or 2-h oral
glucose tolerance test (OGTT) (4). How-
ever,itisnoteasytoperformtheOGTTin
primary practice, and it is debatable
whether the FPG concentration alone pro-
vides an accurate diagnosis of diabetes, as
indicated by the estimated 40% of people
who have undiagnosed diabetes (1).
The hemoglobin A1c (A1C) level is
measured in a standardized test that pro-
duces data consistent with those of the
international A1C-derived average glu-
cose and the Diabetes Control and Com-
plications Trial (5,6). The A1C level
provides a reliable measure of chronic
glycemic control without the need for a
fasting or timed sample, and it correlates
well with the risk of long-term diabetes
complications and mortality (7,8). Sev-
eral population-based studies have inves-
tigated the utility of the A1C level for
detecting undiagnosed diabetes and the
potential to use the A1C level as a good
screening tool for type 2 diabetes (9,10).
However, the recent ADA redeﬁnition of
the diagnosis of diabetes using an A1C
level $6.5%, which considers many as-
pects of diagnostic testing and the eco-
nomic burden, raises concerns about the
possible delay in diagnosing diabetes
(11,12). Thus, there is widespread debate
about the appropriate A1C cutoff value
for diagnosing diabetes.
Toevaluatethepredictivevalueofthe
A1ClevelandtoﬁndtheappropriateA1C
cutoff for identifying undiagnosed diabe-
tes and new-onset diabetes over a 6-year
follow-up, we analyzed the data from a
large-scale, prospective cohort study of
people from a homogeneous ethnic back-
ground.
RESEARCH DESIGN AND
METHODS—The design and baseline
characteristics of the Ansung-Ansan co-
hort study have been published by our
group (13). Brieﬂy, it is an ongoing pro-
spective, community-based cohort study
that is part of the Korean Health and Ge-
nome Study, a community-based epide-
miologicalsurveytoinvestigatethetrends
in diabetes and associated risk factors.
The baseline examination was performed
in2001–2002,andbiennialfollow-upex-
aminations will continue through 2010.
The eligibility criteria included an age of
40–69years,residencewithintheborders
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ORIGINAL ARTICLEof the survey area for at least 6 months
before testing, and sufﬁcient mental and
physical ability to participate.
Participants were recruited from the
residents of two Korean communities
within 60 km of Seoul. Ansung is a
representative rural farming community
that had a population of 132,906 in 2000
(14). Of 7,192 eligible individuals in
Ansung, 5,018 were surveyed (70%
response rate) using a cluster-sampling
methodstratiﬁedbyage,sex,andresiden-
tial district. Ansan is a representative ur-
ban community that had a population of
554,998 in 2000 (14). We successfully
recruited 5,020 subjects from 124,775 el-
igible subjects (4.0%) using a random-
sampling method of the local telephone
directory.
At baseline, we excluded 572 (5.7%)
individuals with known type 2 diabetes
and 91 who had an unknown glucose
status. Among 9,375 (4,415 men and
4,960women)participantswithoutapre-
vioushistoryofdiabetes,635(6.8%)were
newly diagnosed with type 2 diabetes at
the baseline examination. Of 8,740 re-
maining nondiabetic subjects, 5,945
(3,022 from Ansung and 2,923 from
Ansan) were included and underwent
repeated examinations during the 6-year
follow-up period. The recall rate was
85.7% at the 2-year follow-up examina-
tion,74.9%atyear4,and66.7%atyear6.
To deal with the bias arising from missing
data,we usedadata-deletionmethodand
found that there was no signiﬁcant bias
caused by loss to follow-up.
Informed written consent was ob-
tained from all participants. The study
protocol was approved by the ethics com-
mittee of the Korean Center for Disease
Control and the Ajou University School of
Medicine Institutional Review Board.
Throughout the study, the same
trained researchers and instruments
were used to collect the data. Anthropo-
metric parameters and blood pressure
were measured by standard methods.
The fasting plasma concentrations of glu-
cose, insulin, total cholesterol, triglycer-
ides, HDL cholesterol, and high-sensitivity
C-reactive protein (hsCRP) were measured
in a central laboratory.
After an 8- to 14-h overnight fast, all
subjects underwent a 2-h 75-g OGTT at
inclusion and biennially. A1C level was
measured using high-performance liquid
chromatography (Variant II; BioRad Lab-
oratories,Hercules,CA).Pancreaticb-cell
function and insulin resistance were cal-
culated by the homeostasis model
assessment (HOMA-b and HOMA-IR,
respectively).
Deﬁnition
For both baseline and during follow-up,
the deﬁnition of diabetes was based on
plasma glucose results during the 75-g
OGTT, deﬁned according to the 1997
ADA criteria: FPG concentration $7.0
mmol/L (126 mg/dL) or 2-h plasma glu-
cose $11.1 mmol/L (200 mg/dL) or cur-
rent treatment by oral antidiabetes drugs
or insulin (15). A family history of diabe-
tes was coded if there was at least one di-
abetic ﬁrst-degree relative. Hypertension
was deﬁn e da ss y s t o l i cb l o o dp r e s s u r e
$140 mmHg or diastolic blood pressure
$90 mmHg or taking antihypertensive
medication.
Statistical analysis
The data are presented as means 6 SD, as
numbers and percentages, or as a relative
risk (RR) with 95% CIs. Fasting insulin,
triglycerides, and hsCRP concentrations
and HOMA-b and HOMA-IR were nor-
malized by logarithmic transformation.
The means were compared by Student
ttestsorbyANCOVA.Forqualitativevar-
iables, the results are expressed as percent-
ages and were compared by c2 or by
logistic regression. Pearson correlation
analysis was used to determine the rela-
tionships between A1C level and plasma
glucose concentration. The diagnostic
properties of the speciﬁc threshold levels
of A1C were evaluated by calculating the
sensitivity, speciﬁcity, and positive and
negative predictive value by the receiver
operating characteristic (ROC) curve.
To decide optimal-cutoff A1C, we were
referencing the Youden-Index (J=maxc
{sensitivity(c) + speciﬁcity(c) 2 1}, for all
possible cutoff values c) (16).
Risk of new-onset diabetes according
to the A1C cutoff was modeled using the
Cox proportional hazards model, after
adjusting for age, and using those variables
withP # 0.25intheage-adjustedcompar-
ison between the diabetic and nondiabetic
groups.Weﬁrstexaminedtheage-adjusted
effects of the A1C cutoff on the 6-year in-
cidence of diabetes (model A). Model B
comprised model A with additional adjust-
mentforanthropometricandsocialparam-
eters. Model C was the adjusted model B
plus triglyceride, HDL cholesterol, and
hsCRP concentrations and HOMA-b and
HOMA-IR. The ﬁnal Cox models fulﬁlled
the proportional hazards assumption.
We compared the predictive perfor-
manceofA1ClevelandFPGconcentration
as continuous variables using the ROC
curves and by calculating the area under
the curves. For detecting undiagnosed
diabetes at baseline by ROC curve anal-
y s i s ,w eu s e dt h eb a s e l i n ed a t ao fp a r t i c -
ipants without a previous history of
diabetes. For incident diabetes after the
6-year follow-up, we used the 6-year
follow-up data of participants who were
nondiabetic at baseline and who had com-
pleted the 6-year follow-up. MedCalc soft-
warewasusedtocalculatetheROCcurves;
the signiﬁcance of differences between
areas under these curves was calculated
as shown elsewhere (17). All other ana-
lyses were performed using SPSS soft-
ware (version 12.0; SPSS, Chicago, IL).
Signiﬁcance was deﬁned as P , 0.05 for
two-sided tests.
RESULTS
Baseline characteristics
Of 9,375 participants without a previous
history of diabetes, 635 (6.8%) subjects
revealedpreviouslyundiagnoseddiabetes
at the baseline 75-g OGTT test (Table 1).
The clinical characteristics of participants
withandwithoutundiagnoseddiabetesat
baselineareshowninSupplementaryTable
1. At baseline, the Pearson correlation co-
efﬁcients were 0.759 between A1C level
and FPG and 0.673 between A1C level
and 2-h plasma glucose (all P , 0.001).
Table 1 showed the different charac-
teristics between diabetic converters ver-
sus nondiabetic subjects. Over 6 years,
895 (10.2%) subjects developed new
type 2 diabetes, and the mean follow-up
periods were 5.68 6 0.99 years. After ad-
justing for age, BMI, waist circumference,
blood pressure, FPG,and 2-h plasmaglu-
cose, A1C level, fasting insulin, HOMA-
IR, total cholesterol, triglycerides, and
hsCRP concentrations were higher in
those who developed diabetes. In both
sexes, a family history of diabetes, hyper-
tension, and urban residence (Ansan)
were more frequent in the incident dia-
betic group.
A1C cutoff for detecting undiagnosed
diabetes and predicting progression
to diabetes
Table 2 shows the sensitivity, speciﬁcity,
and positive and negative predictive values
of A1C level for detecting undiagnosed
diabetes and predicting 6-year incident
diabetes at A1C cutoff values of 5.0–
6.6%. For detecting undiagnosed dia-
betes, an A1C cutoff of 5.9% produced
the maximum sum of sensitivity (68%)
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Choi and Associatesand speciﬁcity (91%) by ROC analysis.
Thepositiveandnegativepredictivevalues
of this cut point were 34 and 98%, re-
spectively.
For predicting incident diabetes at
6 years, an A1C level of 5.6% was the
optimal cutoff; the sensitivity, speciﬁcity,
and positive and negative predictive values
ofthis cut pointwere 59,77,31,and 91%,
respectively.
To test the A1C cut points to predict
future diabetes, we tested reliability by
randomly dividing our cohort into the
twogroups.Halfofthecohortwasusedto
deﬁne the cut point and the other half to
testreliabilitybycalculatingtheincidence
andadjustedRRs.TheincidencesandRRs
were 31.7, 37.6, 46.5, 53.3, 58.9, 67.6,
and89.7%and4.9,5.9,8,9.4,10.8,13.8,
and 51.5 at the A1C cutoff of 5.6, 5.7, 5.8,
5.9, 6, 6.2, and 6.6%, respectively.
A1C level and prediction of
new-onset diabetes
The RR of new-onset diabetes in subjects
whose A1C levels were above or below
5.6% was assessed using the Cox pro-
portional hazards model (Table 3). In the
age-adjusted model (model A), an A1C
cutoff $5.6% predicted incident diabetes
in both men and women with a RR of 3.4
(95% CI 2.9–4.1) in men and 4.6 (3.7–
5.7) in women (both P , 0.001). This
increased risk remained after additional
adjusting for other confounding factors
(model C).
Because the A1C level displayed a
signiﬁcant interaction with sex and FPG
concentration, we stratiﬁed by sex and
performed subgroup analysis in the sub-
jects with impaired fasting glucose (IFG)
(Table 3; Supplementary Table 2). A total
of 457 participants had IFG at baseline,
and 138 subjects developed incident di-
abetes during the 6 years. In IFG group at
baseline, an A1C level of 5.8% produced
the highest sum of sensitivity and speci-
ﬁcity for predicting new-onset diabetes at
6 years (Supplementary Table 3). After
multivariate adjustment, those with an
A1C level $5.8% had a 3.5-fold increased
risk of incident diabetes in men and 5.2-
fold increased risk in women. The RR
ofincidentdiabetesincreasedasbaseline
A1C level increased in both the group
with normal glucose tolerance and
with IFG, respectively (Supplementary
Table 2).
ROC curves
Figure 1 shows the ROC curves repre-
senting the sensitivity and speciﬁcity of
the A1C levels in detecting undiagnosed
diabetes (Fig. 1A) and predicting new-
onset diabetes (Fig. 1B)a te a c hp o s s i b l e
A1C cutoff level. The analysis indicated a
high predictive value for A1C level in
screening for undiagnosed diabetes and
in predicting future diabetes.
For the identiﬁcation of undiagnosed
diabetes in the entire study population of
9,375 subjects, the areas under the curve
for A1C level were similar with that for
FPG concentration (0.85 [95% CI 0.84–
0.87]vs.0.88[0.86–0.89];P =0.14).The
optimal FPG cutoff for predicting undiag-
noseddiabeteswas5.5mmol/L(99mg/dL),
with 70% sensitivity and 94% speciﬁcity
(Fig. 1A, dotted line).
For predicting new-onset diabetes
after the 6-year follow-up, the area under
the curve for A1C level was signiﬁcantly
greater than that for FPG concentration
(0.74[95%CI0.72–0.76]vs.0.69[0.67–
0.71]; P , 0.001). For FPG concentra-
tions, the cutoff value of 4.8 mmol/L (87
mg/dL)yieldedthemaximumsumofsen-
sitivity (62%) and speciﬁcity (67%) in
Table 1—Baseline characteristics of men and women who developed or did not develop diabetes at 6 years
Men Women
Not diabetic
at follow-up
Diabetic at
follow-up
Age-adjusted
P
Not diabetic at
follow-up
Diabetic at
follow-up
Age-adjusted
P
n 2,328 478 2,722 417
Age (years) 51.1 6 8.4 52.5 6 8.7 51.6 6 8.7 54.1 6 8.8
BMI (kg/m
2) 24.1 6 2.8 24.8 6 3.1 ,0.001 24.6 6 3.1 26.0 6 3.3 ,0.001
Waist circumference (cm) 83 6 78 5 6 8 ,0.001 81 6 98 5 6 10 ,0.001
Systolic blood pressure (mmHg) 116 6 16 121 6 17 ,0.001 115 6 18 123 6 20 ,0.001
Diastolic blood pressure (mmHg) 76 6 11 78 6 11 ,0.001 73 6 11 77 6 12 ,0.001
FPG (mmol/L) 4.7 6 0.5 5.1 6 0.6 ,0.001 4.6 6 0.4 4.9 6 0.6 ,0.001
2-h glucose (mmol/L) 6.1 6 1.6 8.0 6 1.9 ,0.001 6.6 6 1.5 8.4 6 1.6 ,0.001
A1C (%) 5.3 6 0.3 5.6 6 0.5 ,0.001 5.3 6 0.3 5.8 6 0.5 ,0.001
Fasting insulin (pmol/L) 35.8 3/4 25.4 38.3 3/4 28.1 0.016 41.1 3/4 30.6 46.1 3/4 27.2 ,0.001
HOMA-IR 1.2 3/4 0.9 1.4 3/4 1.1 ,0.001 1.4 3/4 1.1 1.7 3/4 1.0 ,0.001
HOMA-b 105.3 3/4 123.4 84.5 3/4 223.2 ,0.001 139.6 3/4 142.2 120.9 3/4 150.0 ,0.001
Total cholesterol (mmol/L) 5.0 6 0.9 5.1 6 1.0 ,0.001 4.9 6 0.9 5.2 6 0.9 ,0.001
HDL cholesterol (mmol/L) 1.2 6 0.3 1.1 6 0.3 0.026 1.2 6 0.3 1.2 6 0.3 ,0.001
Triglycerides (mmol/L) 1.6 3/4 1.2 1.9 3/4 1.2 ,0.001 1.3 3/4 0.8 1.8 3/4 1.1 ,0.001
hsCRP (mg/dL) 0.12 3/4 0.57 0.14 3/4 0.42 0.005 0.10 3/4 0.60 0.15 3/4 0.25 ,0.001
Serum creatinine (mg/dL) 1.0 6 0.2 1.0 6 0.2 0.072 0.73 6 0.16 0.73 6 0.13 0.898
Hypertension (%) 8.6 14.9 ,0.001 10.9 25.2 ,0.001
Family history of diabetes (%) 9.2 14.0 ,0.001 10.9 17.5 ,0.001
Smoker (%) 46.1 48.2 0.319 2.4 5.6 0.001
Living in urban area (Ansan) (%) 50.1 61.7 ,0.001 45.2 51.3 ,0.001
Sporting activity ($1 per week) (%) 39.2 38.7 0.929 32.9 34.3 0.150
Alcohol intake ($60 Kcal per day) (%) 45.2 49.3 0.053 2.8 4.1 0.042
Child with birth weight .4k g( % ) —— — 11.2 12.3 0.338
Data are means 6 SD, geometric mean 3/4 SD, or column percentage. Comparisons are adjusted for age.
946 DIABETES CARE, VOLUME 34, APRIL 2011 care.diabetesjournals.org
HbA1c for diabetes screening and predictionpredicting new-onset diabetes (Fig. 1B,
dotted line).
CONCLUSIONS—The main ﬁnding
of this study is that the A1C assay was
useful as a screening test for type 2 di-
abetes and as a predictor of future di-
abetes. In our population, an A1C cutoff
of 5.9% was able to identify people with
undiagnosed diabetes, and individuals
with an A1C $5.6% had an increased
risk for progression to type 2 diabetes in-
dependent of other confounding factors.
This was a large, prospective cohort
study that used stringent criteria to di-
agnose diabetes and to evaluate the use-
fulness of A1C level in diabetes screening
and in the prediction of new-onset di-
abetes. In this homogeneous population-
b a s e ds t u d y ,w ea p p l i e dt h eO G T Tt oa l l
participants and used the same instru-
ments and personnel for all clinical
and biochemical assessments during the
6 years.
Use of the A1C level in the diagnosis
of or screening for diabetes has been
debated formanyyears.MostA1Cassays,
such as the National Glycohemoglobin
Standardization Program (18), are stan-
dardized,andrecentexpertcommitteere-
ports suggest an A1C cutoff of 6.5% for
diagnosing diabetes (11). For screening a
generalpopulation,theA1Clevelhassev-
eral advantages over the currently used
FPG concentration or 2-h glucose con-
centration after an OGTT. The A1C assay
doesnotneedafastingortimedsample.It
is a better indicator of chronic glycemic
level, has less preanalytic instability (19),
and has a more consistent relationship
with diabetic microvascular complica-
tions than does FPG concentration
(20,21).However,concernsremainabout
the risk of underdiagnosing people with
overt diabetes when using an A1C cutoff
of 6.5% (12).
Several cross-sectional studies have
evaluated the accuracy of the A1C cutoffs
inscreeningfordiabetes.Inanalysisofthe
National Health and Nutrition Examina-
tion Survey data, Buell et al. (9) reported
that an A1C level of 5.8% showed the
highest sensitivity (86%) and speciﬁcity
(92%) in identifying undiagnosed diabe-
tes when using FPG concentration as the
diagnostic test for type 2 diabetes. In the
current study, the deﬁnition of diabetes
was based on plasma glucose results
from the 75-g OGTT, and the A1C value
of 5.9% was appropriate for detecting un-
diagnosed type 2 diabetes in this Korean
cohort population. In a Japanese study of
OGTTresultsin1,904people,anA1Ccut
point of 5.6% identiﬁed undiagnosed
type 2 diabetes, and this value is used
as a supplementary diagnostic criterion
by the Japanese Diabetes Society (10).
Only a few studies have investigated
the utility of A1C level in predicting new-
onset diabetes. Recent Japanese and
French cohort studies reported that A1C
level is effective in predicting type 2
diabetes (22,23) but was less sensitive
and speciﬁc than FPG concentration for
predicting FPG-deﬁned diabetes (22).
This might be because many people
with an abnormal 2-h glucose concentra-
tion after an OGTT have a normal FPG
concentration (24). We used OGTT to
Table 2—Sensitivity, speciﬁcity, and positive and negative predictive value of increasing A1C cutoff levels for detecting undiagnosed
diabetes and for predicting the incidence of type 2 diabetes at the 6-year follow-up
A1C cutoff (%)
Baseline undiagnosed diabetes Incident diabetes after 6 years of follow-up
Predictive value Predictive value
Sensitivity Speciﬁcity Positive Negative Sensitivity Speciﬁcity Positive Negative
5.0 (21.00 SDs above normal mean) 0.972 0.115 0.074 0.982 0.962 0.121 0.162 0.947
5.1 (20.75 SDs above normal mean) 0.956 0.185 0.079 0.98 0.935 0.198 0.171 0.945
5.2 (20.50 SDs above normal mean) 0.945 0.279 0.087 0.986 0.886 0.302 0.184 0.937
5.3 (20.25 SDs above normal mean) 0.915 0.390 0.098 0.984 0.827 0.419 0.201 0.932
5.4 (0.00 SDs above normal mean) 0.887 0.506 0.115 0.984 0.768 0.547 0.231 0.930
5.5 (0.25 SDs above normal mean) 0.866 0.616 0.141 0.984 0.682 0.665 0.265 0.922
5.6 (0.50 SDs above normal mean) 0.822 0.717 0.174 0.982 0.594 0.769 0.313 0.914
5.7 (0.75 SDs above normal mean) 0.770 0.797 0.216 0.979 0.508 0.847 0.370 0.907
5.8 (1.00 SDs above normal mean) 0.720 0.862 0.274 0.977 0.420 0.908 0.448 0.898
5.9 (1.25 SDs above normal mean) 0.676 0.907 0.344 0.975 0.333 0.947 0.527 0.889
6.0 (1.50 SDs above normal mean) 0.619 0.935 0.411 0.971 0.263 0.967 0.586 0.881
6.2 (2.00 SDs above normal mean) 0.523 0.968 0.544 0.965 0.152 0.987 0.677 0.868
6.6 (3.00 SDs above normal mean) 0.372 0.992 0.771 0.956 0.051 0.999 0.885 0.856
Table 3—The RR of incident type 2 diabetes at the 6-year follow-up in Cox proportional
hazards models based on A1C status at baseline
Men Women
RR (95% CI) P RR (95% CI) P
A1C $5.6% (vs. ,5.6%) in the entire study population
Model A* 3.44 (2.87–4.13) ,0.001 4.60 (3.75–5.66) ,0.001
Model B† 3.17 (2.62–3.84) ,0.001 4.00 (3.24–4.95) ,0.001
Model C‡ 2.41 (1.98–2.93) ,0.001 3.06 (2.46–3.81) ,0.001
A1C $5.8% (vs. ,5.8%) in subjects with IFG
Model A* 3.15 (2.13–4.64) ,0.001 6.29 (3.03–13.05) ,0.001
Model B† 3.57 (2.36–5.41) ,0.001 5.99 (2.83–12.66) ,0.001
Model C‡ 3.47 (2.27–5.29) ,0.001 5.15 (2.39–11.11) ,0.001
There was signiﬁcant interaction between A1C and sex. The interaction between A1C and FPG also was
signiﬁcant.*Ageadjusted.†ModelAandwaistcircumference,familyhistoryofdiabetes,livinginurbanarea,
hypertension,smoking,and alcoholintakewereadjusted.‡ModelBand triglycerides(log),HDLcholesterol,
HOMA-IR (log), HOMA-b (log), and hsCRP (log) were adjusted.
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Choi and Associatesdeﬁne diabetes and found that A1C level
wasindependentlyrelatedtoanincreased
risk of new-onset diabetes, even in those
with IFG at baseline. The predictive value
of the A1C level was greater than that of
the FPG concentration.
Determining the optimal A1C cutoff
for diabetes screening is somewhat ar-
bitrary because the risk of diabetes is
continuous over a range of glycemic
measures. To maximize the diagnostic
efﬁciency, the optimal A1C cutoff should
be considered in balancing both sensitiv-
ity and speciﬁcity. Despite the A1C cutoff
value of 5.6% for identifying individuals
with increased risk of future diabetes, as
was chosen by the Youden Index, it
showed only 31% of the positive pre-
dictive value. However, we considered
the clinical situation because diabetes is a
common disease and the action for pre-
vention is highly beneﬁcial and does
relatively little harm to healthy subjects.
Our study has some limitations. All
participants were enrolled from Korean
rural and urban communities of homo-
geneous ethnic background, and it is
debatable whether these results can be
generalized.Althoughracialdifferencesin
A1C level have been suggested (25), the
signiﬁcanceofany differencesisnotclear,
and the use of different A1C values ac-
cording to ethnicity is not currently rec-
ommended. However, after multivariate
adjustment of confounders, A1C level re-
mainedasanindependentpredictorofin-
cident diabetes. In addition, the stringency
of our study method and prospective
follow-upofalargecommunity-basedco-
hort for 6 years make our results stronger
than those of other studies.
In conclusion, we found that A1C
level was effective and convenient for
diabetes screening. An A1C cutoff of
5.9% may identify a high proportion of
people with undiagnosed type 2 diabetes.
Individuals with A1C $5.6% have an in-
creased risk for future diabetes, and early
preventive intervention could be helpful.
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